Lilly just announced that the FDA has approved its Humalog 200 units/mL KwikPen (insulin lispro) for type 1 and type 2 diabetes, making it the first concentrated mealtime insulin analog to reach the US market. The pen has already been launched in Europe following its approval there last October. No pricing information for the KwikPen in the US is available at this time.